#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17496	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2067	839.7	0	.	n	.	0	A69G	SNP	69	69	A	287	287	G	1006	G	935	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17496	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2067	839.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1668	1668	T	941	T,C	876,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17496	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2067	839.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1402	1402	C	995	C	933	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	17496	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2067	839.7	0	HET	.	.	.	C1525T	.	1525	1525	C	1743	1743	C	787	C,T	572,154	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31480	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3682	853.1	0	.	n	.	0	T695C	SNP	695	695	T	1109	1109	C	991	C,T	925,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31480	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3682	853.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2385	2385	C	1043	C,T	962,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31480	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3682	853.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2459	2459	A	1027	A	969	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	31480	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3682	853.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3011	3011	C	889	C	834	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2548	folP	855	855	100.0	folP.l15.c30.ctg.1	1697	149.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1047	1049	AGC	296;294;293	A;G;C	277;276;270	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	7158	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3493	204.4	1	SNP	p	S91F	1	.	.	271	273	TTC	673	675	TTC	245;242;245	T;T;C	231;228;231	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	7158	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3493	204.4	1	SNP	p	D95G	1	.	.	283	285	GGC	685	687	GGC	239;242;239	G;G;C	220;227;225	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	7158	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3493	204.4	1	SNP	p	G95N	0	.	.	283	285	GGC	685	687	GGC	239;242;239	G;G;C	220;227;225	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2042	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1383	147.1	0	.	p	.	0	D79N	NONSYN	235	237	GAT	562	564	AAT	266;265;265	A;A;T	242;240;242	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	2042	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1383	147.1	1	SNP	p	G45D	0	.	.	133	135	GGC	460	462	GGC	243;248;247	G;G;C	232;236;234	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1098	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1135	96.4	0	.	n	.	0	A197.	DEL	197	197	A	723	723	A	247	A	233	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	0	.	p	.	0	E91G	NONSYN	271	273	GAG	638	640	GGG	226;224;227	G;G;G	215;215;217	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	1	SNP	p	D86N	0	.	.	256	258	GAC	623	625	GAC	209;211;213	G;A;C	198;195;204	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	1	SNP	p	S87I	0	.	.	259	261	AGT	626	628	AGT	214;213;217	A;G;T	201;199;206	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	1	SNP	p	S87W	0	.	.	259	261	AGT	626	628	AGT	214;213;217	A;G;T	201;199;206	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	1	SNP	p	S87R	0	.	.	259	261	AGT	626	628	AGT	214;213;217	A;G;T	201;199;206	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5850	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2981	195.4	1	SNP	p	S88P	0	.	.	262	264	TCC	629	631	TCC	217;218;221	T,A;C,G;C	207,1;206,1;211	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5138	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2648	193.5	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1591	1593	CAC	226;227;226	C;A,G;C	214;214,1;214	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5138	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2648	193.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1540	1542	GGC	261;259;255	G;G;C	244;241;234	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1280	1282	GCA	253;254;252	G,A;C;A	232,1;234;234	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1283	1285	ATC	255;254;256	A;T;C	235;235;235	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1295	1297	GTG	257;254;253	G;T;G	238;234;235	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1295	1297	GTG	257;254;253	G;T;G	238;234;235	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1799	1801	ACC	210;211;211	A;C;C	197;199;201	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1853	1855	ACG	208;211;208	A;C;G,T	179;182;176,1	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1853	1855	ACG	208;211;208	A;C;G,T	179;182;176,1	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1976	1978	GGC	208;202;201	G;G;C	197;192;187	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1985	1987	GGC	199;195;196	G;G;C	184;182;181	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4686	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2419	193.1	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2003	2005	CTG	190;193;194	C,G;T;GCCC,GCCCC	147,9;137;143,1	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6844	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3102	219.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1670	1672	CCG	244;247;247	C;C;G	221;231;226	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2838	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1744	162.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	491	491	C	199	C	187	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	373	375	GCC	330;328;326	G;C;C	304;304;300	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	409	411	GAA	321;323;322	G;A;A	295;295;292	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	N124S	NONSYN	370	372	AAT	667	669	AGT	248;245;249	A,C;G;T	236,1;232;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	697	699	GAT	254;251;252	G;A;T,G	236;237;238,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	820	822	TCA	302;298;298	T;C;A	275;271;273	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	949	951	GTC	255;256;254	G,A;T;C,G	237,1;240;238,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	F222S	NONSYN	664	666	TTT	961	963	TCT	260;259;261	T;C,T;T,C	244;246,2;248,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	A323V	NONSYN	967	969	GCC	1264	1266	GTC	216;215;213	G;T;C	208;207;206	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1279	1281	GCA	229;232;234	G;C;A	222;224;224	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	1	SNP	p	G120K	1	.	.	358	360	AAG	655	657	AAG	254;249;249	A;A;G	236;235;233	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	1	SNP	p	A121D	1	.	.	361	363	GAC	658	660	GAC	247;246;249	G;A;C	229;226;233	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3298	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1489	220.0	1	SNP	p	D121N	0	.	.	361	363	GAC	658	660	GAC	247;246;249	G;A;C	229;226;233	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	12474	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4787	259.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1960	1962	CAT	262;261;256	C;A;T	245;242;237	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1394	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	933	148.5	1	SNP	p	V57M	1	.	.	169	171	ATG	472	474	ATG	263;265;267	A;T;G	256;255;255	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
